JP7095992B2 - 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 - Google Patents

可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 Download PDF

Info

Publication number
JP7095992B2
JP7095992B2 JP2017530141A JP2017530141A JP7095992B2 JP 7095992 B2 JP7095992 B2 JP 7095992B2 JP 2017530141 A JP2017530141 A JP 2017530141A JP 2017530141 A JP2017530141 A JP 2017530141A JP 7095992 B2 JP7095992 B2 JP 7095992B2
Authority
JP
Japan
Prior art keywords
cells
pharmaceutical composition
antibody
adcc
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017530141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502068A (ja
JP2018502068A5 (enExample
Inventor
チャン ジェイ． リ，
シアム ウニラマン，
Original Assignee
１グローブ バイオメディカル カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by １グローブ バイオメディカル カンパニー， リミテッド filed Critical １グローブ バイオメディカル カンパニー， リミテッド
Publication of JP2018502068A publication Critical patent/JP2018502068A/ja
Publication of JP2018502068A5 publication Critical patent/JP2018502068A5/ja
Application granted granted Critical
Publication of JP7095992B2 publication Critical patent/JP7095992B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2017530141A 2014-12-08 2015-12-08 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用 Active JP7095992B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462089097P 2014-12-08 2014-12-08
US62/089,097 2014-12-08
US201562200557P 2015-08-03 2015-08-03
US62/200,557 2015-08-03
PCT/US2015/064572 WO2016094456A1 (en) 2014-12-08 2015-12-08 Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020198225A Division JP2021035994A (ja) 2014-12-08 2020-11-30 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用

Publications (3)

Publication Number Publication Date
JP2018502068A JP2018502068A (ja) 2018-01-25
JP2018502068A5 JP2018502068A5 (enExample) 2018-12-13
JP7095992B2 true JP7095992B2 (ja) 2022-07-05

Family

ID=56108081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017530141A Active JP7095992B2 (ja) 2014-12-08 2015-12-08 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用
JP2020198225A Pending JP2021035994A (ja) 2014-12-08 2020-11-30 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020198225A Pending JP2021035994A (ja) 2014-12-08 2020-11-30 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用

Country Status (11)

Country Link
US (2) US12247062B2 (enExample)
EP (1) EP3230311B1 (enExample)
JP (2) JP7095992B2 (enExample)
KR (1) KR102654033B1 (enExample)
CN (1) CN107108718B (enExample)
AU (1) AU2015360642B2 (enExample)
CA (1) CA2968987C (enExample)
NZ (1) NZ732073A (enExample)
RU (1) RU2725807C2 (enExample)
SG (1) SG11201704124YA (enExample)
WO (1) WO2016094456A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
JP7095992B2 (ja) 2014-12-08 2022-07-05 １グローブ バイオメディカル カンパニー， リミテッド 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用
EP3796934A4 (en) * 2018-05-23 2022-04-06 Manysmart Therapeutics, Inc. BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP7748944B2 (ja) * 2020-06-30 2025-10-03 株式会社ガイアバイオメディシン Ｎｋ細胞と抗体との結合を安定化する方法、及びその利用
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526414A (ja) 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 脱免疫化抗ｃｄ３抗体
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
EP0826696B1 (de) * 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
US7786279B2 (en) * 2003-02-27 2010-08-31 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection
ZA200601699B (en) * 2003-10-16 2007-05-30 Micromet Ag Multispecific deimmunized CD3-binders
BRPI0507649A (pt) * 2004-02-16 2007-07-10 Micromet Ag molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit
CA2676098A1 (en) * 2007-01-23 2008-07-31 Zymogenetics, Inc. Soluble fcgammaria and related methods
US8043621B2 (en) * 2007-05-10 2011-10-25 Ramot At Tel Aviv University Ltd. Recombinant fusion protein and polynucleotide construct for immunotoxin production
CA2824279A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
WO2013086636A1 (en) * 2011-12-15 2013-06-20 The Royal Institution For The Advancement Of Learning/Mcgill University Soluble igf receptor fc fusion proteins and uses thereof
ES2680151T3 (es) * 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
JP7095992B2 (ja) 2014-12-08 2022-07-05 １グローブ バイオメディカル カンパニー， リミテッド 可溶性ユニバーサルａｄｃｃ増強合成融合遺伝子およびペプチド技術ならびにその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526414A (ja) 2003-06-02 2006-11-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 脱免疫化抗ｃｄ３抗体
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
US20120294857A1 (en) 2010-01-11 2012-11-22 Trustees Of Dartmouth College Monomeric Bi-Specific Fusion Protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ａｎｎｕ． Ｒｅｖ． Ｉｍｍｕｎｏｌ．， ２００１， ｖｏｌ． １９， ｐｐ． ２７５－２９０

Also Published As

Publication number Publication date
KR20170089003A (ko) 2017-08-02
JP2018502068A (ja) 2018-01-25
EP3230311A4 (en) 2018-05-30
EP3230311A1 (en) 2017-10-18
CA2968987A1 (en) 2016-06-16
US20220235115A1 (en) 2022-07-28
AU2015360642B2 (en) 2019-04-04
NZ732073A (en) 2019-04-26
RU2017124141A (ru) 2019-01-10
CA2968987C (en) 2022-05-10
CN107108718A (zh) 2017-08-29
AU2015360642A1 (en) 2017-06-08
WO2016094456A1 (en) 2016-06-16
KR102654033B1 (ko) 2024-04-02
RU2017124141A3 (enExample) 2019-06-19
EP3230311B1 (en) 2022-01-26
JP2021035994A (ja) 2021-03-04
RU2725807C2 (ru) 2020-07-06
SG11201704124YA (en) 2017-06-29
US12247062B2 (en) 2025-03-11
US20170362299A1 (en) 2017-12-21
CN107108718B (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
US11649293B2 (en) Method for enhancing humoral immune response
US20220235115A1 (en) Soluble Universal ADCC-Enhancing Synthetic Fusion Gene and Peptide Technology and Its Use Thereof
US11660340B2 (en) Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
US9540442B2 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
US11505605B2 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function
JP2021501606A (ja) Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
US20200255493A1 (en) Novel Synthetic Biology-Based ADCC Technology
KR20200131272A (ko) Cd39에 결합하는 항체 및 이의 용도
KR102412805B1 (ko) 세포 면역 요법을 위한 조성물 및 방법
CN117980330A (zh) 同源二聚化肽和包含其的抗体
EP4200325A1 (en) Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor
RU2822366C2 (ru) Химерные антигенные рецепторы и связывающие агенты, нацеленные на dll3
WO2025006499A2 (en) Gpc3-targeted molecules and uses thereof
HK1239703A1 (en) Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
HK1229842A1 (en) Novel synthetic biology-based adcc technology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201222

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201223

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20210212

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20210216

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20211007

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220114

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220502

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220531

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220623

R150 Certificate of patent or registration of utility model

Ref document number: 7095992

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250